Who are SC golimumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Humira, Abrilada, etanercept or adalimumab, Infliximab [infliximab biosimilar 3], infliximab, etanercept, adalimumab, Adalimumab, etanercept, infliximab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sc-golimumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SC golimumab — Competitive Intelligence Brief

SC golimumab (SC golimumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TNF-alpha inhibitor. Area: Immunology.

phase 3 TNF-alpha inhibitor TNF-alpha Immunology Biologic Live · refreshed every 30 min

Target snapshot

SC golimumab (SC golimumab) — Merck Sharp & Dohme LLC. SC golimumab is a monoclonal antibody that binds to tumor necrosis factor-alpha (TNF-alpha), preventing its interaction with cell surface TNF receptors and subsequent inflammatory response.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SC golimumab TARGET	SC golimumab	Merck Sharp & Dohme LLC	phase 3	TNF-alpha inhibitor	TNF-alpha
Humira	ADALIMUMAB	AbbVie	marketed	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	marketed	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01
etanercept or adalimumab	etanercept or adalimumab	University of Glasgow	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Infliximab [infliximab biosimilar 3]	infliximab-infliximab-biosimilar-3	Pfizer	marketed	monoclonal antibody	tumor necrosis factor-alpha (TNF-alpha)
infliximab, etanercept, adalimumab	infliximab, etanercept, adalimumab	University Hospital, Strasbourg, France	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)
Adalimumab, etanercept, infliximab	Adalimumab, etanercept, infliximab	University of Padova	marketed	TNF-alpha inhibitor	TNF-alpha (tumor necrosis factor-alpha)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TNF-alpha inhibitor class)

Abbott · 4 drugs in this class
Centre for Human Drug Research, Netherlands · 2 drugs in this class
Samsung Bioepis Co., Ltd. · 2 drugs in this class
Alvotech Swiss AG · 2 drugs in this class
UCB Pharma · 2 drugs in this class
Celltrion · 2 drugs in this class
AbbVie (prior sponsor, Abbott) · 2 drugs in this class
Assistance Publique Hopitaux De Marseille · 1 drug in this class
Asan Medical Center · 1 drug in this class
Carmel Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SC golimumab — Competitive Intelligence Brief. https://druglandscape.com/ci/sc-golimumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab